Vein Occlusion Articles & Analysis
6 news found
Eylea (aflibercept 2 mg) is the standard of care treatment for macular edema secondary to RVO and is approved for central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) in over 100 countries worldwide. ...
ByBayer AG
About VEGF and aflibercept solution for injection into the eye Aflibercept 2 mg solution for injection into the eye, also known under its brand name Eylea®, has been approved in over 100 countries for five indications for adults, which includes the treatment of neovascular (wet) age-related macular degeneration (nAMD) and the treatment of visual impairment due to: macular edema following ...
ByBayer AG
“The use of the Surfacer System enabled us to quickly and efficiently obtain central venous access after two previous attempts to recanalize the central vein occlusion using other approaches were unsuccessful.” “The case reported presented by Dr. ...
Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By ...
“The use of femoral catheters in patients undergoing hemodialysis is associated with an increased risk of complications including infection and iliac vein stenosis/occlusion,” stated Mathew Smeds, MD, Professor and Chief of the Division of Vascular Surgery in the Department of Surgery at the Saint Louis University School of Medicine and co-author of ...
Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By ...